Marathon Pharmaceuticals is an organization in the sector of biopharmaceutical that focuses on creating and launching new medications for rare diseases. Unlike many prominent pharmaceutical organizations, Marathon pharmaceuticals concentrates on hard-to-produce medicines, on a small scale. The firm then makes available these medications to patients with minimal if any, options of treatment. In addition to this, Marathon explores a channel of treatments for strange cancers, as well as neurological disorders including other conditions.
Marathon pharmaceuticals has its main offices in Northbrook, Illinois. Apart from the head office, the company has other offices in New Jersey and Chicago. The organization just pronounced that it is opening a Marathon Bioscience Center in River North District in Chicago. The facility is housing clinical, research as well as regulatory staff who are accountable for creating novel therapies for cancer, the diseases of the nervous system, movement disorders, endocrine deficiencies, and gastrointestinal diseases. The creation of all these therapies is very vital to the mission of Marathon Pharmaceutical to work with patients with rare diseases or unmet medical conditions. The Bioscience Center of Marathon is situated near to MATTER, a center for healthcare and biotechnology startups.
Marathon Pharmaceuticals also concentrates on essential medicines that tend to be hard to produce like Amytal sodium, a barbiturate imitative that serves as a sedative-hypnotic. In addition to this, Marathon markets Seconal Sodium, another Barbiturate derivative which serves as insomnia’s short-term treatment.
Most of the medications that Marathon pharmaceuticals creates are for adult patients. However, the company’s newest product primarily aims at helping children. Lidocaine hydrochloride monohydrate or Zingo is a tool that offers local anesthetic to help patients handle the venous access pain, such as when blood is being drawn or before surgery. The device is easy to use as well as needle-free and sterile. The device has a button that is pushed to deliver to the application site a 0.5mg dose of pounded lidocaine. Children usually experience fear that comes along with venous access, and that is why when ZINGO was released, it created a lot of excitement amongst medical specialists. Marathon Pharmaceuticals claims that it realized the clinicians’ demand of caring for their patients and had to ensure that they achieved this needs with ZINGO.